Page 54«..1020..53545556..6070..»

46 NONPROFIT, COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS IN THE NORTHEAST U.S. … – PR Newswire

Posted: June 14, 2024 at 2:44 am

Businesses, Hospitals, Municipal Buildings, Museums, Schools, Landmarks To Illuminate In Red On World Sickle Cell Awareness Day To Show Support of Sickle Cell Warriors, Raise Awareness of Sickle Cell Disease, Advocate For A Universal Cure

Fraternal Organization, Global Healthcare Company, NFL Team, Building Owners Management Association Join Campaign

PHILADELPHIA, June 13, 2024 /PRNewswire/ -- A collaborative of 46 nonprofit, community-based organizations and medical providers in the Northeast U.S. is set to Shine the Light on Sickle Cellon June 19, World Sickle Cell Awareness Day. This collaborative initiativewhich includes the illuminationin red of businesses, hospitals, municipal buildings, museums, schools, and other landmarksaims to unite individuals and communities in support of sickle cell warriors, raise awareness of Sickle Cell Disease (SCD) and advocate for a universal cure.Fraternal organization Phi Beta Sigma Fraternity, Inc., global healthcare company Novo Nordisk Inc., the Baltimore Ravens, and Building Owners Management Association-Philadelphia will also join the campaign that is supported by the federal Health Resources and Services Administration (HRSA) as part of the Sickle Cell Disease Treatment Demonstration Project.

"Now in its sixth year, Shine the Light on Sickle Cell is a powerful testament to what we can achieve when communities, healthcare providers, and advocates unite," said Johns Hopkins University School of Medicine Professor Dr. Rosalyn Stewart. "Our goal is to make Sickle Cell Disease as common a topic as COVID or HIV and to inspire action towards a future where Sickle Cell Disease is better understood, better treated, and ultimately cured."

SCD is a genetic blood disorder that disproportionately affects individuals of African descent yet remains widely misunderstood and underrepresented in public discourse. With over 100,000 people in the U.S. affected by SCD and millions more carrying the Sickle Cell Trait, the need for improved access to care and research advancements is critical. Individuals living with SCD often face numerous health complications, including stroke, acute chest syndrome, and chronic organ damage, leading to a significantly reduced life expectancy compared to the general population and earning them the name of sickle cell warrior. Despite these challenges, there is currently no universal cure for SCD.

"I am deeply committed to shining the light on sickle cell and advocating for better care of people with the disease, a disease that causes severe episodic and chronic pain. Those with sickle cell disease frequently report poor interpersonal treatment within health-care settings," said Dr. Sophie Lanzkron, Director of the Division of Hematology at Thomas Jefferson University. "Eliminating the discrimination in health-care settings is imperative as research has proven its correlation with greater pain severity, stress, depression, and sleep issues."

Shine the Light on Sickle Cell primarily operates in the Northeast region, encompassing New England, the mid-Atlantic, Virginia, West Virginia, the U.S. Virgin Islands, and Puerto Rico. Shine the Light on Sickle Cell's hallmark is the illumination of landmark structures and buildings in red the emblematic color of the blood cell associated with the genetic disorder and a symbol of the urgency, passion, and unwavering determination in the fight against this disease in the U.S. and around the world on and around June 19.

Major landmarks that will Shine the Light on Sickle Cell this year include the Franklin Institute, the Hospital of the University of Pennsylvania, and Boathouse Row (Philadelphia); Novo Nordisk headquarters (Plainsboro Township, New Jersey); the Baltimore Ravens' M&T Bank Stadium and the Johns Hopkins University Dome (Baltimore); the Rhode Island State House (Providence); and University of Maryland's Capital Region Medical Center, Bowie Health Center, and Laurel Medical Center (Washington, D.C. metropolitan area).

Zemoria Brandon is a longtime sickle cell advocate whose husband passed away from the disease in 1998. Now in her role as chair of the Shine the Light on Sickle Cell Steering Committee and administrator/social worker with Sickle Cell Disease Association of America, Philadelphia/Delaware Valley Chapter, Ms. Brandon said: "By illuminating our communities in red, we are symbolizing the urgency and passion needed to address the challenges of Sickle Cell Disease. Although Shine the Light on Sickle Cell began six years ago as an initiative in the Northeastern United States, it grew into a campaign, and now it has become a movement. It is uplifting to have seen participation from 29 states across the country and 21 countries around the world."

Organizations in the collaborative are set to engage their community in various activities, including sickle celebrations, candlelight vigils, blood drives, awareness walks, wearing red, posting photos and videos on social media, and more. Shine the Light on Sickle Cell events (click for details and registration information) include:

Join the conversation about Shine the Light on Sickle Cell using #shinethelightonsicklecell2024.

About Shine the Light on Sickle Cell

Shine the Light on Sickle Cell is an annual community awareness campaign to celebrate World Sickle Cell Awareness Day on June 19 as proclaimed by the United Nations in 2008 and to advocate for a universal cure. Shine the Light on Sickle Cell is led by a collaborative of 46 nonprofit, community-based organizations and medical providers in the Northeast United States, SiNERGe (Sickle Cell Improvement in the Northeast Region through education), whose aim is to increase awareness of Sickle Cell Disease and advocate for treatments and better outcomes for individuals with the disease. Learn more at Shine the Light on Sickle Cell.

Media ContactShinePR for Shine the Light on Sickle Cell[emailprotected]

Participating organizations and provider organizations include (by state):

Connecticut

Citizens for Quality Sickle Cell Care* University of Connecticut

Delaware

Christiana Care Sickle Cell Association of Delaware

District of Columbia

Faces of Our Children Sickle Cell Association of the National Capital Area Inc.

Maine

Maine Medical Center

Maryland

Adult and Pediatric to Adult Sickle Cell Clinic, Johns Hopkins University Armstead-Barnhill Foundation for Sickle Cell Anemia Association for the Prevention of Sickle Cell Anemia Inc., Harford and Cecil Counties and the Eastern Shore* Christopher Gipson Sickle Cell Moyamoya Foundation Eastern Shore of Maryland Sickle Cell Association Johns Hopkins University Maryland Sickle Cell Disease Association* Project Spirit Sickle Cell Sally's Sunshine Foundation Sickle Cell Coalition of Maryland William E. Proudford Sickle Cell Fund Inc.

Massachusetts

Boston University Massachusetts General Hospital Massachusetts Sickle Cell Disease Association*

New Hampshire

Dartmouth Hitchcock Medical Center

New Jersey

Donna T. Darrien Memorial Foundation for Sickle Cell Newark Beth Israel Medical Center Sickle Cell Association of New Jersey*@

New York

Candice's Sickle Cell Fund^ Children's Hospital of Monefiore New York Sickle Cell Advisory Network NYC Health + Hospitals New York Sickle Cell Advocacy Network (formerly Queens Sickle Cell Anemia Network)* Sickle Cell Advocates of Rochester^ Sickle Cell Awareness Foundation Corp International Sickle Cell Thalassemia Patients Network*@ Sickle Cell Warriors of Buffalo^ Westchester Sickle Cell Outreach

Pennsylvania

Children's Sickle Cell Foundation Inc.*#@ Crescent Foundation@ Sickle Cell Disease Association of America, Philadelphia/Delaware Valley Chapter*#@ South Central Pennsylvania Sickle Cell Council*# Hospital of the University of Pennsylvania

Puerto Rico

Anemia Falciforme Sickle Cell Disease en Puerto Rico

Rhode Island

Rhode Island Hospital

Vermont

University of Vermont

Virginia

Life and Family Foundation Richmond (formerly Living with Sickle Cell RVA) Sickle Cell Association Inc.*

West Virginia

CAMC Institute for Academic Medicine

*Chapters of the Sickle Cell Disease Association of America (SCDAA)#Members of the Pennsylvania Sickle Cell Disease Providers Network (PASCDPN)^Affiliates of Sickle Cell Thalassemia Patients Network (SCTPN)@HRSA Newborn Screening Grantees

SOURCE Shine the Light on Sickle Cell

Read more:
46 NONPROFIT, COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS IN THE NORTHEAST U.S. ... - PR Newswire

Posted in Cell Medicine | Comments Off on 46 NONPROFIT, COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS IN THE NORTHEAST U.S. … – PR Newswire

UMich researchers distinguish renal cell carcinoma biomarkers to diagnose rare subtypes – The Michigan Daily

Posted: June 14, 2024 at 2:44 am

In a recent study by University of Michigan and other institutions, including Washington University in St. Louis and Johns Hopkins University School of Medicine, identified distinct biomarkers that could help to identify and diagnose unique subtypes of renal cell carcinoma. The study, published May 3 in Cell Reports Medicine, was headed by Alexey Nesvizhskii, professor of bioinformatics and pathology, and focused on identifying a rarer category of the cancer to help to develop more specific treatments in the future.

Renal cell carcinoma accounts for approximately nine out of 10 cases of kidney cancers. RCCs form as tumors, or masses of cancer cells, in the tubules within the kidney. These tubules are key to the organs function, filtering urine and sending nutrients into the blood. About 70% to 80% of patients of renal cell carcinoma have the clear cell RCC subtype.

The remaining cases battle non-clear cell RCC tumors, a much rarer and less-studied version of the disease. Clear cell RCCs are the more common type of RCC, and they appear different under a microscope because of their clear appearance. In an interview with The Michigan Daily, Rahul Mannan, research investigator at the Michigan Center for Translational Pathology, said the rarity of non-clear cell RCCs affects a patients treatment options.

This one category (that) gets most of the attention is the clear cell kidney cancer, and it has got a type of treatment possible with good type of prognosis, Mannan said. What doesnt get attention is this 15%, a sort of a basket case in which we have all these different types of very different looking, weird looking kidney cancers which look differently on morphology. They perform differently on the usual chemotherapy.

Nesvizhskiis lab previously conducted studies to characterize clear cell RCCs, but this most recent study chose to focus on identifying and characterizing the non-clear cell RCCs. The researchers received data from high-quality samples of these unique RCCs from the National Cancer Institutes Clinical Proteomic Tumor Analysis Consortium, which they then analyzed for unique biomarkers that would help identify which type of renal cell carcinoma a patient has.

In an interview with The Daily, Saravana Mohan Dhanasekaran, associate research scientist at the Michigan Center for Translational Pathology, said the tumor samples came from a number of countries before being analyzed in the United States.

The samples are also coming from many different institutes across the world, Dhanasekaran said. They all are collected and centrally processed in locations in the U.S. Then our part comes after the data is generated. There are a lot of different data types that are generated.

The study took multiple approaches to classifying and understanding data on the samples. Dhanasekaran said researchers analyzed both the proteins and genetic makeup of the non-clear cell RCCs to understand the features of each subtype.

There are a lot of different data types that are generated, Dhanasekaran said. In the genomics itself, you have the DNA data, you have the RNA data. Then on the proteomics side, you have whole protein data and then changes that happened on top of the protein, which we call post-translational modification And then how to put together and integrate your analysis of this and understand what kind of disease features are associated in terms of survival of patients or in terms of other fine features of the disease, its a really, really complex analysis.

The biomarkers can come in many different forms, allowing researchers to classify a tumor in a variety of ways. Dhanasekaran said the identifiers could be measured in the DNA of a tumor, the transcribed RNA levels of a gene or in a protein made via the RNA.

The DNA gene is located and then, when it is transcribed by an RNA polymerase, you make the RNA copy of the gene and then this RNA copy then needs to be translated by ribosomes to make the protein level, Dhanasekaran said. So you have these multiple levels that you can monitor.

Once researchers identified a biomarker for a subtype within the data, tests were performed to ensure that the biomarker morphologically expressed itself in the tumor. Mannan said he used the patient tissue samples to validate the biomarker targets through immunohistochemistry, which demonstrates the presence of specific proteins or antigens with a microscope, and RNA in-situ hybridization, which reveals mRNA transcripts within the tissues.

This is what pathologists do we morphologically evaluate, Mannan said. After we have done that selection and confirmation that this is this tumor, then we perform these IHCs or in-situ hybridization.

One particular discovery of the study was a biomarker that distinguishes chromophobe RCC, a malignant tumor, from oncocytoma RCC, a similar but benign tumor. Mannan said the researchers discovered that the chromophobe subtype had higher levels of a protein called Transmembrane glycoprotein NMB or GPNMB, while the benign oncocytoma RCC had higher levels of a gene called Microtubule-associated protein RP/EB family member 3 or MAPRE3 .

It is very clear cut (that IHC) shows the presence of GPNMB in chromophobe and negative in oncocytoma, and expression of MAPRE3 in oncocytoma, negative for chromophobe, Mannan said. Thats what we wanted, to have a sort of a biomarker panel which can differentiate both of them. That was very interesting. So we utilize immunohistochemistry.

The study also discovered that tumors with genome instability, or an increased risk of mutation, can be identified by their unusually increased production of genes named IGF2BP3 and PYCR1. Dhanasekaran said the findings could help to identify high-risk patients and improve their treatment.

Determining one major thing was looking at why certain patients have a poorer (chance of) survival, Dhanasekaran said. We found out that many of those patients had a phenomenon called genome instability, meaning that the DNA in this patients tumor (was) not very stable and so we thought, Can we identify biomarkers that can track this disease subset?

The potential of identifying unique non-clear cell RCC subtypes could allow doctors to tailor treatments to specific types of kidney cancer. However, Bioinformatics Ph.D. student Yi Hsiao, a first author on the study, said that even with the new biomarkers, the rarity of non-clear cell RCCs means treatment options remain limited.

This rare subtype actually doesnt have much progress on different treatments, Yi said. Understanding the underlying difference is another objective of the study. So, we can identify some proteins that you might find of interest among other cancers. They definitely require further experimental validation, but at least initially, you have some ideas that support a possible solution to those rare subtypes. Right now they all belong to the kidney cancer treatment.

Even though treatment for non-clear cell RCCs is still limited, Dhanasekaran said that this studys work has given pathologists greater potential to diagnose the uncommon disease, which could lead to better patient care.

Current biomarkers that (are) used for this disease diagnosis, they are kind of a limited set that you have, Dhanasekaran said. Many of them are also not very specific, for a specific subtype of kidney cancer. So what this study did is infused that space with a lot more biomarkers that we can use to make much finer diagnoses. Especially in the rare cancer area.

Summer News Editor Marissa Corsi can be reached at macorsi@umich.edu.

View post:
UMich researchers distinguish renal cell carcinoma biomarkers to diagnose rare subtypes - The Michigan Daily

Posted in Cell Medicine | Comments Off on UMich researchers distinguish renal cell carcinoma biomarkers to diagnose rare subtypes – The Michigan Daily

City of Hope CAR T Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial – BioSpace

Posted: June 14, 2024 at 2:44 am

LOS ANGELES--(BUSINESS WIRE)-- Treating prostate cancer with immunotherapy is currently difficult to do. But preliminary results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer had minimal side effects with the cellular immunotherapy and had promising therapeutic activity, according to a study published today in Nature Medicine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612751963/en/

Saul Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and Tanya Dorff, M.D., City of Hope section chief, Genitourinary Disease Program, and their teams worked together on the phase 1 clinical trial using a City of Hope-developed CAR T cell therapy for prostate cancer. (Photo: Business Wire)

The trial treated 14 prostate stem cell antigen (PSCA)-positive patients who had metastatic castration resistant prostate cancer (mCRPC), which had spread beyond the prostate and no longer responded to hormone treatment, using CAR T cell therapy. More than 34,000 men with this type of prostate cancer die each year in the United States.

Saul Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and team developed CAR T cells that target prostate stem cell antigen (PSCA) found to be highly expressed in prostate cancer. The treatment took a patients immune cells known as T cells from the bloodstream, and reprogrammed the cells in a laboratory with a CAR to recognize and attack the PSCA protein on the surface of cancer cells. CAR T cells were then infused back into the patients system to destroy cancer cells.

Prostate cancer has been called an immune desert the tumor microenvironment is difficult to treat with immunotherapies because you dont get a lot of T cells inside the tumor, said Tanya Dorff, M.D., City of Hope section chief, Genitourinary Disease Program, and professor, Department of Medical Oncology & Therapeutics Research. It takes something really powerful to overcome that. Our study showed that City of Hopes CAR T cell therapy for prostate cancer could be a step closer to doing that.

Our trials preliminary major finding is that PSCA-directed CAR T cells may be effective against mCRPC, Priceman added. This opens up the opportunity to continue to develop this type of cellular immunotherapy for these patients, who currently have no other effective treatment options.

The trials goals were to examine the therapys safety and dose-limiting toxicities, or side effects that limit the amount of treatment that can be administered, as well as preliminary data on the treatments efficacy in patients.

The studys findings were:

One patient who had received several prior therapies responded well to the CAR T cell therapy. His PSA level decreased by 95% and cancer in his bones and soft tissue also declined. He experienced this positive response for approximately eight months.

The patients results were very encouraging, and we are deeply grateful for his participation in our study as well as other patients and their families, Dorff said. We want to continue with this therapy and increase the amount of CAR T cells, and continue to carefully monitor for any health problems, as we think this can improve the therapys effectiveness.

The phase 1b trial using the PSCA-CAR T cell therapy in combination with radiation to enhance anti-tumor activity aims to enroll up to 24 patients.

City of Hope, a recognized leader in CAR T cell therapies, has treated nearly 1,500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has about 70 ongoing CAR T clinical trials, which include 13 different solid tumor types. The trials use City of Hope-developed therapies and industry-sponsored products. A recent study published in Nature Medicine featured City of Hopes CAR T cell therapy for brain tumors.

City of Hope manufactured the CAR T cells in its own facility, the Cell Therapy Production Center on its Los Angeles campus.

The Prostate Cancer Foundation helped fund the trial.

About City of Hope

City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hopes growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hopes affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612751963/en/

Saul Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and Tanya Dorff, M.D., City of Hope section chief, Genitourinary Disease Program, and their teams worked together on the phase 1 clinical trial using a City of Hope-developed CAR T cell therapy for prostate cancer. (Photo: Business Wire)

Read this article:
City of Hope CAR T Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial - BioSpace

Posted in Cell Medicine | Comments Off on City of Hope CAR T Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial – BioSpace

Cell Therapy Tools Studies Medication for Dogs in Pain – Orange County Business Journal

Posted: June 14, 2024 at 2:44 am

One clinical-stage biotech firm is making arthritis injectable drug treatments not for humans, but for pets.

Irvine-based Cell Therapy Tools (CTT) aims to develop cell-based therapies for pain and inflammation, starting with osteoarthritis in dogs.

The company last month said that it has begun enrolling dogs with the degenerative joint disease in a three-month clinical study using its experimental drug product Chondroshield.

During osteoarthritis, theres cartilage under destruction because of biochemical processes happening in the joint, Chief Executive Fari Izadyar told the Business Journal.

Chondroshield is going to reverse that process.

Izadyar said that this upcoming pilot study is the first step toward gaining approval from the Food and Drug Administrations Center for Veterinary Medicine.

CTT plans to enroll 20 dogs in the study, which will be overseen by Chief Veterinary Medical Officer Robert Jeff Mayo in Washington.

Izadyar said the company is currently self-funded but is open to fundraising once CTT has more clinical data.

We are hoping that the closer we get to the finish line, we can go to the fundraising phase, he said.

Canine Arthritis?

Chondroshield is intended to be an off-the-shelf product that can be stored in the fridge until needed for use by a veterinarian.

The drugs formulation utilizes platelets. Mainly known for blood clotting, platelets also have wound-healing properties that help stimulate regeneration of tissue.

Existing cell therapies for canine osteoarthritis typically involve some sort of surgery to extract cells from the patients body.

The issue, however, is that production for these therapies is labor-intensive and the quality can be inconsistent, according to Izadyar.

Clinicians cannot verify how many platelets are in there or what is the growth factor composition, Izadyar said.

Chondroshield, on the other hand, is an allogenic cell-based therapy, which means the cells come from donors instead of the patient and doesnt require any blood collection.

Izadyar said there is an unmet need in the market for such a treatment with there being close to 80 million dogs owned per household in the U.S. and 20% of them suffer from osteoarthritis.

As part of the pilot study, CTT is also partnering with New York-based pet tech startup Maven and will use its smart collars to monitor pet activity.

It will give us objective data as to how movement and mobility of the animal improved or not after this study, Izadyar said.

Stem Cell Research

Izadyar got his veterinary degree nearly four decades ago from the University of Tehran.

As a practitioner, Izadyar said he saw animal patients with debilitating chronic diseases that couldnt be treated with traditional medical therapy.

It was frustrating. Izadyar said.

The experience pushed him to return to school and pursue a doctorate in reproductive biology at Utrecht University in the Netherlands where he became more involved in stem cell research.

I was fascinated by the powerful healing ability of cells, Izadyar said.

He left the Netherlands for the U.S. in 2004 and went on to be chief scientific officer at local biotech companies developing cell-based products for regeneration purposes, including Santa Ana-based PrimeGen Biotech LLC and its subsidiary VetCell Therapeutics that was created in 2015.

After working at these companies, Izadyar realized he wanted to make his own product and joined CTT in 2022.

Read this article:
Cell Therapy Tools Studies Medication for Dogs in Pain - Orange County Business Journal

Posted in Cell Medicine | Comments Off on Cell Therapy Tools Studies Medication for Dogs in Pain – Orange County Business Journal

Tampa Bay residents among those alleging Ozempic caused stomach paralysis – Tampa Bay Times

Posted: June 14, 2024 at 2:44 am

Tony Thompson thought he was taking a type of insulin when he was prescribed Ozempic to treat his diabetes in 2021.

The Zephyrhills resident gave himself the medication through weekly injections. After a few weeks, he found himself barely eating and favorite meals like hamburgers and fries began to smell awful to him. He quickly shed 17 pounds.

Soon after that, Thompson, 60, began to suffer severe stomach pains. His condition deteriorated even more on a trip to Georgia when he reached a fourth day without a bowel movement. The pain was so bad, he said, friends had to drive him home as he couldnt risk taking his return flight.

He also blames the drug for later developing pancreatitis, which required surgery to remove his gallbladder.

I felt like I was a chemo patient, he said. I couldnt stand the smell of food.

Thompson and other Tampa Bay residents are among thousands who have joined a mass legal action against Novo Nordisk, the manufacturer of Ozempic and Wegovy, a similar drug used for obesity. The lawsuit claims that the company failed to warn patients that Ozempic, hailed as a miracle drug for those battling diabetes and obesity, causes gastroparesis, also known as stomach paralysis.

Both Wegovy and Ozempic work by tricking the body into feeling that its full. Thats achieved through an ingredient known as a semaglutide, which mimics the GLP-1 hormone produced by the body when eating. They also slow the progress of food through the digestive system.

In September, the Food and Drug Administration updated Ozempics labeling to add ileus, a temporary condition when the intestines stop working properly and cant push food and waste out of the body, as a reported adverse reaction to the drug. There is no warning about gastroparesis.

Three recent preliminary studies found that patients using GLP-1 drugs are at a higher risk for gastroparesis, according to a CNN report.

GLP-1 drugs have soared in popularity in recent years with Medicare paying out $5.7 billion in 2022 for three popular brands, according to research by KFF. About one in eight Americans have taken GLP-1 type drugs, according to a KFF survey.

Those patients were put at risk by Novo Nordisk, which should have known about the risks to the gastrointestinal system, said Andrew Van Arsdale, a managing partner of AVA Law Group, which is representing about two thousand users of the medications.

There are some very dangerous side effects and these manufacturers have an obligation to put patients, consumers, doctors in the best position they can to make that risk benefit analysis to take that product, he said. Thats all were asking here.

Subscribe to our free DayStarter newsletter

Well deliver the latest news and information you need to know every morning.

Want more of our free, weekly newslettersinyourinbox? Letsgetstarted.

With 18 lawsuits filed in 11 court districts, the legal challenge is proceeding through a single test case filed on behalf of a Michigan women, who the lawsuit states she was hospitalized on Jan. 4 for extreme pain, vomiting and stomach paralysis that required an endoscopic procedure. She also was given painkillers for an inflamed esophagus.

Novo Nordisk disputes the allegations in the lawsuits and said in a company statement provided to the Tampa Bay Times that it plans to contest the cases. GLP-1 medicines have been used to treat type 2 diabetes for more than 18 years, and for the treatment of obesity for 8 years, it states.

Novo Nordisk stands behind the safety and efficacy of all of our GLP-1 medicines when they are used as indicated and when they are taken under the care of a licensed healthcare professional, the statement reads.

Go here to read the rest:
Tampa Bay residents among those alleging Ozempic caused stomach paralysis - Tampa Bay Times

Posted in Diabetes | Comments Off on Tampa Bay residents among those alleging Ozempic caused stomach paralysis – Tampa Bay Times

The American Diabetes Association Kicks Off the 84th Scientific Sessions with Breakthrough Diabetes Research – PR Newswire

Posted: June 14, 2024 at 2:44 am

Leading Diabetes Scientific Sessions Meeting Will Present Groundbreaking Data on Key Topics Including: Obesity, Technology, AI Health and the Latest in Diabetes Innovation

ORLANDO, Fla., June 13, 2024 /PRNewswire/ -- From June 2124, the American Diabetes Association (ADA) will host the 84th Scientific Sessions in Orlando, FL. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening more than 11,000 leading physicians, scientists, researchers and health care professionals from around the globe. The hybrid meeting will feature the latest scientific findings in diabetes, including more than 200 sessions and 2,000 original research presentations at the Orange County Convention Center.

Diabetes is among the top 10 leading causes of death in the United States, with more than 1.4 million new cases diagnosed each year. Over the past 20 years, the number of adults diagnosed with diabetes has more than doubled due to factors like increased obesity, weight gain and aging. During the annual meeting, the ADA is highlighting the latest cutting-edge advances in diabetes research and care.

Among the key themes, you can expect:

"As we commence the 84th Scientific Sessions, we are proud of our program that underscores our commitment to addressing the multifaceted challenges of diabetes," said Robert Gabbay, MD, PhD, the ADA's chief scientific and medical officer. "This year's program reflects our dedication to advancing research, fostering innovation, and ultimately improving the lives of those affected by diabetes. We look forward to an engaging and impactful event that will inspire and drive the future of diabetes care, at a pivotal time of pharmacological and technological advances in the field."

Other notable topics and themes highlighted in the presentations at the 84th Scientific Sessions include eye health, health disparities, diabetes and obesity related cancers, and early risk monitoring. Most sessions, in addition to the 60-plus livestreamed sessions, will be available for on-demand viewing for attendees following the meeting through August 26.

"This year's Scientific Sessions is set to highlight the latest and greatest advances in diabetes research with an exceptional, data-driven program," said Alice Y.Y. Cheng, MD, FRCPC, chair of the 84th Scientific Sessions Planning Committee. "Whether you're joining us in-person or virtually, you'll have the opportunity to engage with leading experts, participate in dynamic discussions, and gain valuable insights that will drive the future of diabetes care."

Learn more about the 84th Scientific Sessions.For access to program navigation, educational session information, news updates, abstracts, and exhibitor information, the 2024 ADA Scientific Sessions mobile app and the online planner are your go-to meeting resources.

For more information, please contact the ADA Scientific Sessions media at [emailprotected].

Embargo Policy:

Oral presentations: Oral presentations are embargoed from the time of submission until the start of their presentation at the 84th Scientific Sessions.

Symposiums (including late-breaking symposiums): Symposiums and presentations within symposiums are embargoed until the beginning of the Symposium session at the 84th Scientific Sessions.

Poster presentations (including late-breaking posters): Poster presentations are embargoed from the time of submission until Friday, June 21, 2024, at 6:30 p.m. ET.

About the American Diabetes Association's Scientific SessionsThe ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

SOURCE American Diabetes Association

More:
The American Diabetes Association Kicks Off the 84th Scientific Sessions with Breakthrough Diabetes Research - PR Newswire

Posted in Diabetes | Comments Off on The American Diabetes Association Kicks Off the 84th Scientific Sessions with Breakthrough Diabetes Research – PR Newswire

Senator Collins and Usher talk diabetes screening in Washington – NewsCenterMaine.com WCSH-WLBZ

Posted: June 14, 2024 at 2:44 am

The Republican senator met with the famous musician in Washington D.C. to talk about screenings for Type 1 diabetes.

MAINE, USA Sen. Susan Collins met with famous R&B artist Usher in Washington D.C. to discuss the available screenings for Type 1 diabetes, on Thursday.

Usher told Collins, R-Maine, about his son who has Type 1 diabetes (TD1) and advocated for better access to diabetes screening for families, to increase early detection, according to a press release from Collins' office.

Type 1 diabetes can occur in all ages but is the most common type of diabetes in children, according to the Centers for Disease Control and Prevention.

During their meeting, Collins and Usher discussed the impact screening and early detection can have. They agreed it would allow families time to plan and prepare for a life with the disease and provide opportunities for individuals to participate in clinical trials or other therapies that could help delay clinical onset, the release stated.

Collins recently introduced the Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act with Senator Jeanne Shaheen, D-New Hampshire, to improve early detection, according to the release.

"This bill would direct the CDC to conduct a national public awareness campaign about the signs and symptoms of T1D for both healthcare providers and the public, as well as the benefits of early detection and screening," the release stated.

"Early detection of Type 1 diabetes can prevent life-threatening conditions like diabetic ketoacidosis and potentially allow for the use of therapeutics to delay the clinical onset of the condition, helping to improve patients' quality of life and reliance on insulin," Collins stated. "It was a pleasure to talk about the importance of Type 1 diabetes screening with Usher in Washington and hear about his impressive son. I thanked Usher for lending his voice and platform to increasing awareness of the burden of Type 1 diabetes."

See the original post here:
Senator Collins and Usher talk diabetes screening in Washington - NewsCenterMaine.com WCSH-WLBZ

Posted in Diabetes | Comments Off on Senator Collins and Usher talk diabetes screening in Washington – NewsCenterMaine.com WCSH-WLBZ

Development, validation and visualization of a web-based nomogram for predicting risk of new-onset diabetes after … – Nature.com

Posted: June 14, 2024 at 2:44 am

This study was conducted using medical record data from four centers in three provinces and cities of China and has thus pioneered the construction of a clinical prediction model for NODAP and implemented risk stratification. This study represents the first attempt to establish a nomogram and an online web-based risk calculator for predicting the risk of NODAP. At a median follow-up of 4.6 years (IQR, 2.38.6 years), the incidence of NODAP was established at 46.52%. The risk of NODAP can be appropriately evaluated through FPG level, LDL-C level, hypertension, family history of diabetes and use of diuretics. Our study is the first to report the long-term NODAP incidence rate in Chinese patients with ACS post-PCI, suggesting a high risk of new-onset diabetes that necessitates widespread attention. The prediction model we developed underwent internal and external validation with results, indicating good predictability.

Our predictive model revealed that the long-term incidence of NODAP exceeds the reported incidence of type 2 diabetes in the Chinese population15. Having a history of ACS might serve as an independent risk factor for new-onset diabetes, aligning with results drawn from other cohort study16. Nearly half of patients who undergo PCI must manage diabetes-related medical burden, thus underscoring the importance of appropriate and timely prediction of NODAP. Currently, there are more than 30 prediction models for the incidence of diabetes, each based on different populations17, with some models predicting the risk of new-onset diabetes in patients with coronary heart disease8. However, only one previous study has focused on the risk factors and incidence of NODAP in the Asian population6, with a lack of NODAP prediction models. Our study used rigorous methodology to tackle challenges such as missing data, model building, and internal and external validation, providing a clearer understanding of the groups at high-risk of NODAP.

Glycolipid metabolism levels were identified as significant risk factors for predicting the risk of NODAP, a conclusion that aligns with the findings of several prior studies that developed models to predict new diabetes onset8,18,19. Chun et al. determined through univariate and multivariate regression analyses that the risk factors for NODAP include FPG level100mg/dL, TG level150mg/dL, high body mass index (BMI), and high-intensity statins and that FPG is more influential than other factors6. FPG levels are significantly associated with the risk of diabetes20, and each 1 mg/dL increase in FPG leads to a 9% increase in the risk of diabetes, not only in patients with impaired fasting glucose, but also even in patients with normal FPG levels (9099mg/dL)21. 2 h postprandial glucose (2hPG) is also an indicator for detecting blood glucose levels, but studies have shown that the inclusion of 2hPG and insulin resistance in the prediction model did not significantly improve the predictive accuracy of the model22,23, and therefore NODAP risk prediction by incorporating a convenient and economical FPG is reliable and practical.

There is a consensus that higher LDL-C levels lead to an increased risk of cardiovascular events24,25, and LDL-C levels are the primary therapeutic target for lipid-lowering therapy in patients with coronary artery disease. Meanwhile, LDL-C has also been found to be associated with an increased risk of diabetes26,27, and the mechanism may be related to abnormal cholesterol metabolism affecting pancreatic -cell membrane function and pancreatic cholesterol deposition, which leads to pancreatic -cell dysfunction affecting glucose metabolism28,29,30. The prediction model in this study showed that LDL-C was also a very strong predictor of NODAP, and LDL-C levels were also significantly associated with the onset of NODAP, so controlling LDL-C levels in patients has the additional benefit of preventing and controlling the development of NODAP in addition to the reduced cardiovascular benefit31, but the specific mechanism of the effect of LDL-C on NODAP has yet to be investigated.

Family history of diabetes is a well-known risk factor for type 2 diabetes32, and the same results were obtained in this study for NODAP. Family history increases the risk of diabetes mellitus, which is thought to be mediated by a combination of genetic, environmental, and lifestyle pathways. Genetic susceptibility to diabetes mellitus has been demonstrated by several genome-wide association studies (GWAS), which have linked susceptibility location to pancreatic -cell dysfunction, insulin resistance, and other factors33.

In addition, this study showed that NODAP risk was strongly associated with a history of hypertension rather than with transient values of BP. Hypertension and diabetes mellitus share multiple metabolic syndrome phenotypes including higher body mass index. abdominal obesity, hyperinsulinemia and hypertriglyceridemia34,35, and pathological processes such as dysregulation of reninangiotensinaldosterone system (RAAS), insulin resistance, and inflammation in hypertension can contribute to diabetes mellitus36,37. Therefore, our findings suggest that closer attention should be paid to glycemic indicators in patients undergoing PCI with hypertension.

Although a history of hypertension and a family history of diabetes are non-modifiable factors, evidence from several randomized controlled trials has demonstrated that the onset of diabetes can also be effectively delayed by improving lifestyle38,39. Therefore, our findings suggest that closer attention should be paid to the glycemic indexes of patients undergoing PCI with a family history of hypertension and diabetes, and consideration should be given to reducing the risk of NODAP through stricter lifestyle control.

Patients undergoing PCI are more likely to have hypertension and poor cardiac function and have more complex medications. Therefore, in our study we also considered the influence of prescribed medications, including antihypertensive drugs, psychotropic drugs, diuretics, and various types and intensities of statins on NODAP. We ultimately identified significant correlations between diuretics and NODAP, aligning with the outcomes of several clinical studies40,41. The mechanism by which diuretics affect glucose metabolism is mostly thought to be an indirect effect on insulin secretion due to diuretic-induced hypokalemia42, but its benefits in terms of reducing the occurrence of cardiovascular events are much greater43, and therefore it is still possible to use this drug for treatment with a combination of potassium-preserving diuretics or increased potassium supplementation and thus improvement of glucose metabolism, although the exact mechanism has not yet been fully elucidated44. This suggests that in patients at high risk of NODAP who require diuretic therapy, combined potassium-preserving measures may be considered to reduce the risk of morbidity. Previously, diuretics have also been found to have a dose-related effect on diabetes, and small doses of diuretics may not increase insulin resistance or insulin release45,46. We have not conducted further studies on the dose to be explored in the future. While previous studies on patients post-PCI have indicated that statin treatment increases the risk of NODAP by 27%11, and high-intensity statin treatment increases the risk of NODAP by 48%6, our study did not establish any association between statins or high-intensity statins and an increased risk of NODAP. Considering that the cardiovascular benefits of statin drugs considerably outweigh the adverse effects of new-onset diabetes47,48, statin drugs remain the primary choice for patients post-PCI.

In this study, we revealed that NODAP is a consequence of the combined effects of factors such as genetics, metabolism, and medication. We classified the risk of NODAP into low (11.339.7%), moderate (39.852.8%), and high (52.990.0%) risk. This stratification allows for improved formulation of post-PCI lifestyle and preventive antidiabetic regimens. Specifically, in the clinic, we can provide active NODAP preventive treatment to patients in advance based on their risk prediction results combined with diabetes prevention and treatment guidelines49. For example, if a patient is screened as intermediate risk, it is recommended that he/she should first control modifiable NODAP risk factors, including improving lifestyle, controlling glucose and lipid levels, etc. If he/she is screened as high risk, it is recommended that he/she should carry out intensive lifestyle interventions, including dietary control, exercise and avoiding the use of diuretics as much as possible. This study provides a precise risk calculator for patients with NODAP as well as prompts healthcare workers, especially those in the cardiovascular field, to pay attention to new-onset diabetes and underscores the urgent need for proactive NODAP prevention.

Despite its strengths, there are several limitations to this study: first, it relies on data from hospitals across three provinces and cities in China, with data from the chosen regions being both limited and unevenly spread, thus there may be selection bias. The long follow-up duration of the study may introduce potential attrition bias, and the precise onset date of diabetes could not be determined. Second, this research is a database-oriented retrospective study; therefore, there may be reporting inaccuracies or missing variables, such as height, weight and waist circumference reflecting obesity and type of ACS, number of diseased vessels, and number of stents implanted reflecting severity of the condition, as well as the inevitable recollection bias of the case data. And it was also not possible to obtain variable characteristics of lifestyle, dietary patterns, and frequency of exercise that may also affect NODAP. The lack of comprehensiveness of the variables covered also resulted in an inability to effectively compare with previous diabetes prediction models. Third, there are many differences between the training and validation cohort population characteristics, which may be related to the fact that the two parts of the cohort came from different provinces, different hospitals, and different severity of the disease, etc. More research centers, larger sample sizes, and more research variables need to be included to further externally validate the model efficacy. Additionally, the laboratory indicators used for diagnosing new-onset diabetes were dependent on glycated, fasting, and random blood glucose levels, which may not fully represent the long-term blood glucose control. Future research using oral glucose tolerance test results could potentially offer higher diagnostic sensitivity and precision. Lastly, we have only established a NODAP prediction and risk stratification system, and have not studied the prognosis of patients at different risks with different treatment modalities, nor have we been able to determine a causal relationship. Further studies are needed to investigate the effects of different management strategies on the long-term prognosis of patients undergoing PCI and the specific mechanisms linking these factors to NODAP.

Read more here:
Development, validation and visualization of a web-based nomogram for predicting risk of new-onset diabetes after ... - Nature.com

Posted in Diabetes | Comments Off on Development, validation and visualization of a web-based nomogram for predicting risk of new-onset diabetes after … – Nature.com

Plasma Metabolite Score Associated with Diabetes Risk and Psychological Distress – Physician’s Weekly

Posted: June 14, 2024 at 2:44 am

The following is a summary of A Plasma Metabolite Score Related to Psychological Distress and Diabetes Risk: A Nested Case-control Study in US Women, published in the June 2024 issue of Endocrinology by Huang, et al.

For a study, researchers sought to investigate the association between a metabolomic signature for psychological distress and the risk of developing diabetes.

A nested case-control study was conducted within the Nurses Health Study, involving 728 women with incident diabetes and 728 matched controls. Plasma metabolomics data were collected between 1989 and 1990, and incident diabetes was diagnosed between 1992 and 2008. Based on prior research, a weighted plasma metabolite-based distress score (MDS) comprised of 19 metabolites was calculated. Conditional logistic regression was used to estimate odds ratios (OR) and 95% CI for diabetes risk according to MDS, adjusting for matching and other diabetes risk factors.

After adjustment for sociodemographic factors, family history of diabetes, and health behaviors, the OR for diabetes risk across quintiles of MDS ranged from 1.00 (reference) for the lowest quintile to 2.47 for the highest quintile. Each standard deviation increase in MDS was associated with a 36% higher diabetes risk (95% CI: 1.21, 1.54; P-trend <.0001). This association was moderately attenuated after additional adjustment for body mass index (comparable OR: 1.17; 95% CI: 1.02, 1.35; P-trend = .02). The MDS explained 17.6% of the association between self-reported psychological distress and diabetes risk (P = .04).

The MDS showed a significant association with diabetes risk in women. The findings suggested that differences in lipid and amino acid metabolites may contribute to the link between psychological distress and diabetes risk.

Reference: academic.oup.com/jcem/article-abstract/109/6/e1434/7471893

See the original post:
Plasma Metabolite Score Associated with Diabetes Risk and Psychological Distress - Physician's Weekly

Posted in Diabetes | Comments Off on Plasma Metabolite Score Associated with Diabetes Risk and Psychological Distress – Physician’s Weekly

A story of liver cancer and diabetes [PODCAST] – Kevin MD

Posted: June 14, 2024 at 2:44 am

Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes!

Join us for a discussion on the critical intersection of diabetes and liver disease. Our guest, Sarah Bauer, a pediatrician, shares her personal journey and insights into the recent screening guidelines released by the American Diabetes Association. From the importance of early detection to bridging the gap between research and practice, we explore actionable steps for improved patient care and advocacy.

Sarah Baueris a pediatrician.

She discusses the KevinMD article, Diabetes and liver disease: urgent screening needs highlighted by personal tragedy.

Our presenting sponsor is Nuance, a Microsoft company.

Do you spend more time on administrative tasks like clinical documentation than you do with patients? Youre not alone. Clinicians report spending up to two hours on administrative tasks for each hour of care provided. Nuance, a Microsoft company, is committed to helping clinicians restore the balance with Dragon Ambient eXperience or DAX for short. DAX is an AI-powered, voice-enabled solution that helps physicians cut documentation time in half. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. DAX Copilot can be easily enabled within the workflow of the Dragon Medical application to bring the power of ambient technology to more clinicians faster while leveraging the proven and powerful capabilities used by over 550,000 physicians.

Explore DAX Copilot today. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo.Discover clinical documentation that writes itself and reclaim your work-life balance.

VISIT SPONSOR https://nuance.com/daxinaction

SUBSCRIBE TO THE PODCAST https://www.kevinmd.com/podcast

RECOMMENDED BY KEVINMD https://www.kevinmd.com/recommended

GET CME FOR THIS EPISODE https://earnc.me/uhdcvq

Powered by CMEfy.

View original post here:
A story of liver cancer and diabetes [PODCAST] - Kevin MD

Posted in Diabetes | Comments Off on A story of liver cancer and diabetes [PODCAST] – Kevin MD

Page 54«..1020..53545556..6070..»